ATE428719T1 - Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors - Google Patents

Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors

Info

Publication number
ATE428719T1
ATE428719T1 AT00948923T AT00948923T ATE428719T1 AT E428719 T1 ATE428719 T1 AT E428719T1 AT 00948923 T AT00948923 T AT 00948923T AT 00948923 T AT00948923 T AT 00948923T AT E428719 T1 ATE428719 T1 AT E428719T1
Authority
AT
Austria
Prior art keywords
nucleic acid
hgf
acid ligands
factor
growth factor
Prior art date
Application number
AT00948923T
Other languages
English (en)
Inventor
Judy Ruckman
Larry Gold
Andrew Stephens
Nebojsa Janjic
Ross Rabin
Michael Lochrie
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/364,539 external-priority patent/US6344321B1/en
Priority claimed from US09/364,543 external-priority patent/US6331394B1/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ATE428719T1 publication Critical patent/ATE428719T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT00948923T 1999-07-29 2000-07-24 Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors ATE428719T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/364,539 US6344321B1 (en) 1990-06-11 1999-07-29 Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US09/364,543 US6331394B1 (en) 1991-06-10 1999-07-29 Nucleic acid ligands to integrins
PCT/US2000/020139 WO2001009159A1 (en) 1990-06-11 2000-07-24 Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met and to integrins

Publications (1)

Publication Number Publication Date
ATE428719T1 true ATE428719T1 (de) 2009-05-15

Family

ID=40577369

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00948923T ATE428719T1 (de) 1999-07-29 2000-07-24 Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors

Country Status (3)

Country Link
US (3) US20030049644A1 (de)
AT (1) ATE428719T1 (de)
DE (1) DE60042021D1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389710B2 (en) * 2004-02-27 2013-03-05 Operational Technologies Corporation Therapeutic nucleic acid-3′-conjugates
FR2867784B1 (fr) * 2004-03-17 2006-06-09 Commissariat Energie Atomique Aptameres selectionnes a partir de cellules vivantes tumorales et leurs applications
KR20080036595A (ko) * 2005-07-05 2008-04-28 가부시키가이샤 리보믹 면역글로불린 ｇ에 결합하는 핵산과 그 이용법
ES2369739T3 (es) * 2006-03-20 2011-12-05 Seikagaku Corporation Agente terapéutico para la artritis reumatoide.
JP4698559B2 (ja) * 2006-11-24 2011-06-08 Ｎｅｃソフト株式会社 ウサギ由来のＩｇＧ抗体に結合性を有する核酸分子
MY183404A (en) 2006-12-19 2021-02-18 Genentech Inc Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
US20110092452A1 (en) * 2008-03-05 2011-04-21 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
CA2734172A1 (en) * 2008-08-29 2010-03-04 Genentech, Inc. Diagnostics and treatments for vegf-independent tumors
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
US8236570B2 (en) 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
US8841429B2 (en) * 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
KR20130000384A (ko) 2010-02-18 2013-01-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 뉴레귤린 길항제 및 암의 치료에서의 그의 용도
US20140148503A1 (en) * 2011-07-20 2014-05-29 University Of Iowa Research Foundation Nucleic acid aptamers
WO2013043715A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
BR112016024319B1 (pt) 2014-04-18 2024-01-23 Acceleron Pharma Inc USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
BR112017021510A2 (pt) 2015-04-06 2018-07-03 Acceleron Pharma Inc heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
CN116327952A (zh) 2015-08-04 2023-06-27 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
EP3370754B1 (de) 2015-11-04 2026-04-29 Acceleron Pharma, Inc. Verfahren zur erhöhung der erythrozytenkonzentration und behandlung von ineffizienter erythropoiese
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
EP3439741B1 (de) 2016-04-06 2026-05-20 Acceleron Pharma Inc Actriib:alk7-heteromultimere zur therapeutischen reduzierung des körpergewichts
CN116531490A (zh) 2016-07-15 2023-08-04 阿塞勒隆制药公司 用于治疗肺高血压的组合物和方法
HUE067225T2 (hu) 2016-07-27 2024-10-28 Acceleron Pharma Inc Mielofibrózis kezelésére szolgáló készítmények
CA3039074A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Compositions and method for treating kidney disease
AU2019216761B2 (en) 2018-02-09 2025-04-10 Acceleron Pharma Inc. Methods for treating heterotopic ossification
EP4054617A4 (de) 2019-11-05 2023-12-27 Acceleron Pharma Inc. Behandlungen für systemische sklerose

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3546807C2 (de) * 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5472841A (en) * 1990-06-11 1995-12-05 Nexstar Pharmaceuticals, Inc. Methods for identifying nucleic acid ligands of human neutrophil elastase
US5731424A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5837834A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US6270472B1 (en) * 1998-12-29 2001-08-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Apparatus and a method for automatically introducing implants into soft tissue with adjustable spacing
US20020165188A1 (en) * 1999-10-14 2002-11-07 Meenhard Herlyn Methods for inhibition of tumorigenic properties of melanoma cells

Also Published As

Publication number Publication date
US20090075922A1 (en) 2009-03-19
US20030049644A1 (en) 2003-03-13
US20060148748A1 (en) 2006-07-06
DE60042021D1 (de) 2009-05-28

Similar Documents

Publication Publication Date Title
DE60042021D1 (de) Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
Streit et al. A role for HGF/SF in neural induction and its expression in Hensen’s node during gastrulation
Tassone et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma
CR6392A (es) Moduladores de ccr5
Zalachoras et al. Opposite effects of stress on effortful motivation in high and low anxiety are mediated by CRHR1 in the VTA
ATE517638T1 (de) Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln
ATE314116T1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
Cook et al. The role of plasma granulocyte colony stimulating factor and bone marrow dysfunction after severe trauma
DE60236206D1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
DE69941429D1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
Li et al. Ultrasound irradiation combined with hepatocyte growth factor accelerate the hepatic differentiation of human bone marrow mesenchymal stem cells
PA8429901A1 (es) Compuestos antipicornavirales y metodos para su uso y preparacion
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
ES2193144T3 (es) Compuestos de dna que comprenden secuencias que codifican manuronano c-5-epimerasa.
D'Rozario et al. Fibroblastic reticular cells provide a supportive niche for lymph node–resident macrophages
TR200402529T4 (tr) Yeni Fenalliloksi fenil türevleri.
DE60128368D1 (de) Diagnose und behandlung von prostatakrebs
DE69634499D1 (de) Verwendungsmethoden von einkernigen phagozyten zur förderung der axonalen regeneration
Anderson et al. CCR6+ γδ T cells home to skin wounds and restore normal wound healing in CCR6-deficient mice
Garn et al. Phenotypical and functional characterization of alveolar macrophage subpopulations in the lungs of NO2-exposed rats
Stocks et al. Development of human innate immune responses in a humanized mouse model expressing four human myelopoiesis transgenes
GB9610281D0 (en) Diagnostic method and apparatus
Duque et al. EGCG and Taxifolin Modulate Secretory Activity and Expression of Dentinogenesis Markers in Odontoblast‐Like Cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties